Diagnostic Innovation
A minimally invasive, blood-based diagnostic concept designed to support earlier diagnosis.
Anaxa is developing a diagnostic test based on the detection of Biomarker 143 in blood samples. The approach is intended to support the diagnostic evaluation of patients with suspected sarcoidosis.
The test concept is designed to be compatible with standard laboratory workflows, making it accessible to healthcare providers without requiring specialized equipment or training.
Development is ongoing, with the goal of providing a tool that can help clinicians make more informed diagnostic decisions.
Simple, non-invasive blood collection
Detection of Biomarker 143
Results to support clinical evaluation
Key Advantages
Unlike biopsies or bronchoalveolar lavage, a blood test requires only a simple blood draw, reducing patient burden and risk.
Designed to be compatible with standard laboratory workflows, the test concept could be widely accessible to healthcare providers.
Based on the detection of Biomarker 143 specifically associated with sarcoidosis, distinguishing it from other conditions.
Intended to support, not replace, clinical judgment by providing additional objective data for the diagnostic evaluation.
Potential Impact
Faster diagnosis enables timely treatment initiation, potentially preventing disease progression.
Additional objective data supports clinicians in making more informed treatment choices.
Earlier treatment may help reduce irreversible organ damage and long-term patient suffering.
Learn about the current development status and our roadmap toward bringing this diagnostic approach to clinical practice.